EUCTR2010-021120-96-GB进行中（未招募）不适用
A study to assess the incidence of mutations in the tyrosine kinase domain of the epidermal growth factor receptor in UK patients with newly diagnosed locally advanced or metastatic non-small cell lung cancer and to investigate the quality of life of these patients undergoing first-line monotherapy with erlotinib (Tarceva®). - TRANSCRiPT
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnostic phase:
- •1. Patients able and willing to give written informed consent. Consent must be obtained prior to any study-specific procedure
- •2. Male or female patients aged 18 years.
- •3. ECOG Performance Status 0-3
- •4. Histologically confirmed or working diagnosis (on clinical grounds) of locally advanced (stage TuB with supraclavicular lymph node metastases or malignant pleural or pericardial effusion) or metastatic (stage IV) NSCLC
- •5. Patients with Non-squamous or Squamous advanced NSCLC are to be screened in the diagnostic phase of the study
- •6. Ability to provide adequate biopsy sample for EGFR mutation testing
- •Treatment phase:
- •1. Patients must have been proven to have a histologically confirmed EGFR exon 19 deletion or exon 21 mutation in the diagnostic phase of the study.
- •2. Adequate haematological function:-
- •- Haemoglobin =9 g/dL
- •- Absolute neutrophil count (ANC) =1.5 × 109/L
- •- Platelets =100 × 109/L
- •- APTT in the normal range (1.2 × DLN-1.2 × ULN)
- •3. Adequate liver function:
- •- Aspartate transaminase (AST) and alanine transaminase (ALT) =2.5 × ULN in the absence of liver metastases (AST, ALT =5 × ULN in case of liver metastases)
- •- Total bilirubin =1.5 × ULN
- •- INR =1.5
- •4. Adequate renal function as assessed by the investigator
- •- Creatinine =1.5 × ULN
- •5. Able and willing to comply with the required protocol and follow-up procedures including answering the QoL questionnaire, and able to receive oral medications
- •6. Female patients must be postmenopausal (12 months of amenorrhea), surgically sterile or they must agree to use a physical method of contraception. Male patients must be surgically sterile or agree to use a barrier method of contraception. Women with an intact uterus (unless amenorrhoeic for the last 12 months) must have a negative pregnancy test (urine or serum) within 3 days prior to enrolment into the study. Male and female patients must use effective contraception during the study and for a period of 2 weeks following the last administration of erlotinib
- •7. Patients with asymptomatic and stable (as defined by centre standard) cerebral metastases receiving medical treatment will be eligible for the study. Patients who have received radiation therapy for their cerebral metastases before the initiation of systemic treatment for non-small-cell lung cancer also will be eligible. Radiotherapy can be given but should be completed prior to the initiation of study therapy – a 2 week ‘washout’ period is recommended
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A subject will be excluded if the answer to any of the following statements is yes.
- •Treatment phase:
- •1. Previous treatment for NSCLC with chemotherapy (except for neo-adjuvant or adjuvant chemotherapy completed >6 months prior to consent for diagnostic phase of the study) or therapy against EGFR, either with antibody or small molecule (tyrosine kinase inhibitor).
- •NB: Patients can have received radiotherapy as long as the irradiated lesion is not the only target lesion for evaluating response and as long as radiotherapy has been completed before initiating the study treatment (a 2-week period is recommended).
- •2. Treatment with any investigational drug agent during the 3 weeks before enrollment in the study
- •3. Patients with symptomatic cerebral metastases
- •4. Known hypersensitivity to erlotinib or any of its excipients
- •5. Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
- •6. Positive urine or serum pregnancy test in women of childbearing potential. Patients (male or female) with reproductive potential not willing to use effective method of contraception. Female patients should not be pregnant or breast-feeding.
研究者
相似试验
招募中
不适用
A study of the incidence of molecular mutations in newly diagnosed acute lymphoblastic leukemia (ALL) patients by Next-generation sequencing techniqueThai newly diagnosed ALL patients aged greater than 18 years.Acute lymphoblastic leukemia, Next-generation sequencing ,Molecular mutationsTCTR20240409003Siriraj Hospital Mahidol University140
尚未招募
不适用
A study of incidence of molecular mutations in newly diagnosed acute myeloid leukemia (AML) patients by Next-generation sequencing techniqueewly diagnosed acute myeloid leukemia aged greater than 18 yearsAcute myeloid leukemia, molecular, incidence, next-generation sequencingTCTR20190227003The organization takes responsibility for initiating a study.139
已完成
不适用
Exploratory study on somatic mutation detection using plasma DNA from patients with lung cancerlung cancerJPRN-UMIN000021711Third Department of Internal Medicine, Wakayama Medical University80
招募中
1 期
Study on the correlation between gene mutation and TCM syndrome types in metastatic colorectal cancerMetastatic colorectal cancerITMCTR2100004411onghua Hospital Affiliated to Shanghai University of traditional Chinese Medicine
已完成
不适用
A feasibility study of performance of a novel method for gene mutations in circulating tumor DNAnon-small cell lung cancerJPRN-UMIN000038679West Japan Oncology Group10